Hi-C analysis revealing IGH::MYC, TP53 loss, KMT2A alterations, and a complex genome supported a high-risk DLBCL diagnosis, likely to benefit from targeted clinical trials to optimize treatment outcomes. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.